JP2015531773A5 - - Google Patents

Download PDF

Info

Publication number
JP2015531773A5
JP2015531773A5 JP2015529005A JP2015529005A JP2015531773A5 JP 2015531773 A5 JP2015531773 A5 JP 2015531773A5 JP 2015529005 A JP2015529005 A JP 2015529005A JP 2015529005 A JP2015529005 A JP 2015529005A JP 2015531773 A5 JP2015531773 A5 JP 2015531773A5
Authority
JP
Japan
Prior art keywords
alkyl
group
independently selected
cfh
membered saturated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015529005A
Other languages
English (en)
Japanese (ja)
Other versions
JP6505013B2 (ja
JP2015531773A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/067821 external-priority patent/WO2014033170A1/en
Publication of JP2015531773A publication Critical patent/JP2015531773A/ja
Publication of JP2015531773A5 publication Critical patent/JP2015531773A5/ja
Priority to JP2018207904A priority Critical patent/JP6895938B2/ja
Application granted granted Critical
Publication of JP6505013B2 publication Critical patent/JP6505013B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015529005A 2012-08-28 2013-08-28 スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用 Expired - Fee Related JP6505013B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2018207904A JP6895938B2 (ja) 2012-08-28 2018-11-05 スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
EP12182076 2012-08-28
EP12185055.6 2012-09-19
EP12185055 2012-09-19
EP12190837.0 2012-10-31
EP12190837 2012-10-31
EP13157230 2013-02-28
EP13157230.7 2013-02-28
EP13169574.4 2013-05-28
EP13169574 2013-05-28
EP12182076.5 2013-08-23
PCT/EP2013/067821 WO2014033170A1 (en) 2012-08-28 2013-08-28 Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018207904A Division JP6895938B2 (ja) 2012-08-28 2018-11-05 スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用

Publications (3)

Publication Number Publication Date
JP2015531773A JP2015531773A (ja) 2015-11-05
JP2015531773A5 true JP2015531773A5 (OSRAM) 2018-03-01
JP6505013B2 JP6505013B2 (ja) 2019-04-24

Family

ID=49085019

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2015529007A Withdrawn JP2015533782A (ja) 2012-08-28 2013-08-28 スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用
JP2015529005A Expired - Fee Related JP6505013B2 (ja) 2012-08-28 2013-08-28 スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用
JP2018207904A Expired - Fee Related JP6895938B2 (ja) 2012-08-28 2018-11-05 スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用
JP2018208063A Expired - Fee Related JP6907173B2 (ja) 2012-08-28 2018-11-05 スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用
JP2021095380A Withdrawn JP2021176846A (ja) 2012-08-28 2021-06-07 スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2015529007A Withdrawn JP2015533782A (ja) 2012-08-28 2013-08-28 スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2018207904A Expired - Fee Related JP6895938B2 (ja) 2012-08-28 2018-11-05 スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用
JP2018208063A Expired - Fee Related JP6907173B2 (ja) 2012-08-28 2018-11-05 スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用
JP2021095380A Withdrawn JP2021176846A (ja) 2012-08-28 2021-06-07 スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用

Country Status (27)

Country Link
US (5) US10676429B2 (OSRAM)
EP (2) EP2890375B1 (OSRAM)
JP (5) JP2015533782A (OSRAM)
KR (4) KR20210081451A (OSRAM)
CN (4) CN113321632A (OSRAM)
AP (2) AP2015008248A0 (OSRAM)
AR (2) AR092270A1 (OSRAM)
AU (5) AU2013307331A1 (OSRAM)
BR (2) BR112015004192B1 (OSRAM)
CA (2) CA2880699A1 (OSRAM)
CL (2) CL2015000488A1 (OSRAM)
CR (2) CR20200276A (OSRAM)
EA (2) EA027280B1 (OSRAM)
EC (2) ECSP15007335A (OSRAM)
GT (2) GT201500020A (OSRAM)
HK (2) HK1210030A1 (OSRAM)
IL (3) IL236967A0 (OSRAM)
JO (1) JOP20130256B1 (OSRAM)
MX (2) MX375789B (OSRAM)
NI (2) NI201500029A (OSRAM)
NZ (4) NZ743499A (OSRAM)
PH (3) PH12015500317A1 (OSRAM)
SG (4) SG10201709133QA (OSRAM)
TW (4) TW201920090A (OSRAM)
UA (2) UA122385C2 (OSRAM)
UY (2) UY34992A (OSRAM)
WO (2) WO2014033176A1 (OSRAM)

Families Citing this family (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106957282B (zh) 2011-12-21 2019-08-30 诺维拉治疗公司 B型肝炎抗病毒剂
AR092270A1 (es) * 2012-08-28 2015-04-08 Janssen R&D Ireland Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
SG11201504740UA (en) 2012-12-27 2015-07-30 Univ Drexel Novel antiviral agents against hbv infection
ES2628953T3 (es) 2013-02-28 2017-08-04 Janssen Sciences Ireland Uc Sulfamoilarilamidas y el uso de las mismas como medicamentos para el tratamiento de la hepatitis B
WO2014165128A2 (en) 2013-03-12 2014-10-09 Novira Therapeutics, Inc. Hepatitis b antiviral agents
MX353412B (es) 2013-04-03 2018-01-10 Janssen Sciences Ireland Uc Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
JP6441315B2 (ja) 2013-05-17 2018-12-19 ヤンセン・サイエンシズ・アイルランド・ユーシー スルファモイルチオフェンアミド誘導体およびb型肝炎を治療するための医薬品としてのその使用
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
PL3024819T3 (pl) 2013-07-25 2018-08-31 Janssen Sciences Ireland Uc Pochodne piroloamidowe podstawione glioksamidem i ich zastosowanie jako leków do leczenia wirusowego zapalenia wątroby typu B
SG11201602748XA (en) 2013-10-23 2016-05-30 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
KR20160128305A (ko) 2014-02-05 2016-11-07 노비라 테라퓨틱스, 인코포레이티드 Hbv 감염의 치료를 위한 병용 요법
ES2705401T3 (es) 2014-02-06 2019-03-25 Janssen Sciences Ireland Uc Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la Hepatitis B
PT3116316T (pt) 2014-03-13 2019-09-30 Assembly Biosciences Inc Moduladores alostéricos da proteína do núcleo da hepatite b
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
AU2015295288B2 (en) * 2014-07-31 2019-10-31 Centre National De La Recherche Scientifique (Cnrs) FLT3 receptor antagonists
US9765050B2 (en) 2014-12-30 2017-09-19 Novira Therapeutics, Inc. Pyridyl reverse sulfonamides for HBV treatment
MA41338B1 (fr) 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
SI3321265T1 (sl) 2015-03-04 2020-07-31 Gilead Sciences, Inc. Spojine 4,6-diamino-pirido(3,2-d)pirimidina in njihova uporaba kot modulatorji toličnih receptorjev
EP3271019A1 (en) 2015-03-19 2018-01-24 Novira Therapeutics Inc. Azocane and azonane derivatives and methods of treating hepatitis b infections
WO2016161268A1 (en) 2015-04-01 2016-10-06 Enanta Pharmaceuticals, Inc. Hepatitis b antviral agents
US10738035B2 (en) 2015-05-13 2020-08-11 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US10875876B2 (en) * 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US10179131B2 (en) 2015-07-13 2019-01-15 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US10301255B2 (en) 2015-07-22 2019-05-28 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
AU2016312508A1 (en) 2015-08-26 2018-02-15 Gilead Sciences, Inc. Deuterated toll-like receptor modulators
TWI730985B (zh) 2015-09-15 2021-06-21 美商艾森伯利生物科學公司 B型肝炎核心蛋白質調節劑
JP6845231B2 (ja) 2015-09-29 2021-03-17 ノヴィラ・セラピューティクス・インコーポレイテッド B型肝炎抗ウイルス薬の結晶形態
US10280175B2 (en) 2016-02-02 2019-05-07 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
SG11201807543YA (en) 2016-03-07 2018-09-27 Enanta Pharm Inc Hepatitis b antiviral agents
KR20180129943A (ko) 2016-04-15 2018-12-05 노비라 테라퓨틱스, 인코포레이티드 캡시드 조립 억제제를 포함하는 배합물 및 방법
EP3458455B1 (en) 2016-05-20 2021-06-16 F. Hoffmann-La Roche AG Novel pyrazine compounds with oxygen, sulfur and nitrogen linker for the treatment of infectious diseases
BR102017010009A2 (pt) 2016-05-27 2017-12-12 Gilead Sciences, Inc. Compounds for the treatment of hepatitis b virus infection
EA201892375A1 (ru) 2016-05-27 2019-08-30 Джилид Сайэнс, Инк. Способы лечения инфекций, вызываемых вирусом гепатита b
CA3028228A1 (en) 2016-06-10 2017-12-14 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
EP3484883B1 (en) 2016-07-14 2020-04-15 H. Hoffnabb-La Roche Ag Novel tetrahydropyrazolopyridine compounds for the treatment of infectious diseases
JP7034133B2 (ja) 2016-07-14 2022-03-11 エフ.ホフマン-ラ ロシュ アーゲー 感染性疾患の処置のためのカルボキシ 6,7-ジヒドロ-4H-ピラゾロ[1,5-a]ピラジン化合物
WO2018011163A1 (en) 2016-07-14 2018-01-18 F. Hoffmann-La Roche Ag 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine and 6,7-dihydro-4h-triazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
ES2826748T3 (es) 2016-09-02 2021-05-19 Gilead Sciences Inc Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll
JP6746776B2 (ja) 2016-09-02 2020-08-26 ギリアード サイエンシーズ, インコーポレイテッド Toll様受容体調節剤化合物
AU2017326356A1 (en) 2016-09-15 2019-04-11 Assembly Biosciences, Inc. Hepatitis B core protein modulators
IL308894A (en) 2016-10-14 2024-01-01 Prec Biosciences Inc Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
US10821103B2 (en) 2016-11-07 2020-11-03 Arbutus Biopharma Corporation Substituted pyridinone-containing trycyclic compounds, and methods using same
WO2018086530A1 (zh) * 2016-11-08 2018-05-17 正大天晴药业集团股份有限公司 作为cccDNA抑制剂的磺酰胺类化合物
CN108264520B (zh) * 2017-01-03 2021-12-07 上海长森药业有限公司 用于治疗乙型肝炎的化合物及其用途
TW202510891A (zh) 2017-01-31 2025-03-16 美商基利科學股份有限公司 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
JOP20180008A1 (ar) 2017-02-02 2019-01-30 Gilead Sciences Inc مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
AU2018217664B2 (en) * 2017-02-07 2022-03-03 Janssen Pharmaceutica Nv Sulphamoylaryl derivatives and use thereof as medicaments for the treatment of liver fibrosis
RU2650610C1 (ru) 2017-02-28 2018-04-16 Васильевич Иващенко Александр Противовирусная композиция и способ ее применения
EP3589630B1 (en) 2017-03-02 2021-07-07 Assembly Biosciences, Inc. Cyclic sulfamide compounds and methods of using same
WO2018172852A1 (en) 2017-03-21 2018-09-27 Arbutus Biopharma Corporation Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
RU2666727C1 (ru) * 2017-07-18 2018-09-12 Андрей Александрович Иващенко Ингибитор вируса гепатита В (ВГВ)
EP3672970A1 (en) 2017-08-22 2020-07-01 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
AU2018326474B2 (en) 2017-08-28 2024-07-25 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US11267825B2 (en) 2017-11-02 2022-03-08 Aicuris Gmbh & Co. Kg Highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis B virus (HBV)
CU20200045A7 (es) 2017-11-02 2021-03-11 Aicuris Gmbh & Co Kg Derivados de indol-2-carboxamidas sustituidos con pirazolo-piperidina activos contra el virus de la hepatitis b (vhb)
CN109879799B (zh) * 2017-12-06 2020-08-11 浙江司太立制药股份有限公司 含有4-羰氧基哌啶基的氨磺酰基苯甲酰胺类化合物及其制备方法
US10428070B2 (en) 2017-12-06 2019-10-01 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US10723733B2 (en) 2017-12-06 2020-07-28 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2019123340A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
WO2019123339A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
CN109988126B (zh) * 2017-12-29 2023-05-16 南京富润凯德生物医药有限公司 一种3-氨基-氧杂环丁烷衍生物及其制备方法和应用
US11058678B2 (en) 2018-01-22 2021-07-13 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
WO2019154343A1 (zh) * 2018-02-09 2019-08-15 正大天晴药业集团股份有限公司 衣壳蛋白装配抑制剂、其药物组合物和用途
MY196582A (en) 2018-02-13 2023-04-19 Gilead Sciences Inc PD-1/PD-L1 Inhibitors
KR102526964B1 (ko) 2018-02-26 2023-04-28 길리애드 사이언시즈, 인코포레이티드 Hbv 복제 억제제로서의 치환된 피롤리진 화합물
TW202415645A (zh) 2018-03-01 2024-04-16 愛爾蘭商健生科學愛爾蘭無限公司 2,4-二胺基喹唑啉衍生物及其醫學用途
EP3765011A1 (en) 2018-03-14 2021-01-20 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
WO2019191166A1 (en) 2018-03-29 2019-10-03 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
EP3774883A1 (en) 2018-04-05 2021-02-17 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 2,2,─環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW201945388A (zh) 2018-04-12 2019-12-01 美商精密生物科學公司 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
WO2019204609A1 (en) 2018-04-19 2019-10-24 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2019206072A1 (zh) * 2018-04-24 2019-10-31 浙江海正药业股份有限公司 磺酰胺芳基甲酰胺衍生物及其制备方法和用途
TW202014193A (zh) 2018-05-03 2020-04-16 捷克科學院有機化學與生物化學研究所 包含碳環核苷酸之2’3’-環二核苷酸
US11186579B2 (en) 2018-07-06 2021-11-30 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
CN112384505B (zh) 2018-07-06 2025-05-27 吉利德科学公司 治疗性的杂环化合物
PT3820572T (pt) 2018-07-13 2023-11-10 Gilead Sciences Inc Inibidores pd-1/pd-l1
AU2019300324A1 (en) 2018-07-13 2021-01-21 F. Hoffmann-La Roche Ag Oligonucleotides for modulating RTEL1 expression
EP3597637A1 (en) * 2018-07-19 2020-01-22 Irbm S.P.A. Inhibitors of hepatitis b virus
TWI869058B (zh) 2018-07-27 2025-01-01 加拿大商愛彼特生物製藥公司 經取代四氫環戊[c]吡咯、經取代二氫吡咯,其類似物及使用其之方法
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
CN112955142A (zh) 2018-09-21 2021-06-11 英安塔制药有限公司 官能化杂环化合物作为抗病毒剂
KR20250107952A (ko) * 2018-10-05 2025-07-14 에모리 유니버시티 단량체 및 다량체 항-hbv 제제
CN113195055A (zh) 2018-10-22 2021-07-30 组装生物科学股份有限公司 用于hbv治疗的5元杂芳基甲酰胺化合物
EP3870566A1 (en) 2018-10-24 2021-09-01 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US11071730B2 (en) 2018-10-31 2021-07-27 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
AU2019373090B2 (en) 2018-10-31 2023-05-25 The University Of Sydney Compositions and methods for treating viral infections
PL3873903T3 (pl) 2018-10-31 2024-05-20 Gilead Sciences, Inc. Podstawione związki 6-azabenzimidazolu jako inhibitory hpk1
AR116946A1 (es) 2018-11-02 2021-06-30 Aicuris Gmbh & Co Kg Derivados de urea 6,7-dihidro-4h-pirazolo[4,3-c]piridinas activas contra el virus de la hepatitis b (vhb)
JP2022506351A (ja) 2018-11-02 2022-01-17 アイクリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト B型肝炎ウイルス(hbv)に対して活性を有する新規ウレア6,7-ジヒドロ-4h-チアゾロ[5,4-c]ピリジン
AR117189A1 (es) 2018-11-02 2021-07-21 Aicuris Gmbh & Co Kg Derivados de 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activos contra el virus de la hepatitis b (vhb)
UY38436A (es) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg Nuevas 6,7-dihidro-4h-pirazolo[1,5-a] pirazinindol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
UY38435A (es) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg Nuevas urea 6,7-dihidro-4h-pirazol[1,5-a] pirazinas activas contra el virus de la hepatitis b (vhb)
UY38437A (es) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg Nuevas urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (hbv)
CN113271946A (zh) 2018-11-21 2021-08-17 英安塔制药有限公司 官能化杂环化合物作为抗病毒剂
TWI827760B (zh) 2018-12-12 2024-01-01 加拿大商愛彼特生物製藥公司 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
MA55020A (fr) 2019-02-22 2021-12-29 Janssen Sciences Ireland Unlimited Co Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
US20220143061A1 (en) 2019-03-07 2022-05-12 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
CN113543851B (zh) 2019-03-07 2025-03-18 捷克共和国有机化学与生物化学研究所 2’3’-环二核苷酸及其前药
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
AU2020265390A1 (en) 2019-04-30 2021-12-23 Aicuris Gmbh & Co. Kg Novel phenyl and pyridyl ureas active against the hepatitis B virus (HBV)
CN113748113A (zh) 2019-04-30 2021-12-03 艾库里斯有限及两合公司 具有抗乙型肝炎病毒(hbv)活性的新型吲哚嗪-2-甲酰胺类化合物
AU2020266258A1 (en) 2019-04-30 2021-12-23 Aicuris Gmbh & Co. Kg Novel oxalyl piperazines active against the hepatitis B virus (HBV)
PH12021500047A1 (en) 2019-04-30 2023-01-23 Aicuris Gmbh & Co Kg Novel indole-2-carboxamides active against the hepatitis b virus (hbv)
AR119732A1 (es) 2019-05-06 2022-01-05 Janssen Sciences Ireland Unlimited Co Derivados de amida útiles en el tratamiento de la infección por vhb o de enfermedades inducidas por vhb
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
CA3140103A1 (en) 2019-05-24 2020-12-03 Assembly Biosciences, Inc. Pharmaceutical compositions for the treatment of hbv
WO2020241814A1 (ja) * 2019-05-29 2020-12-03 国立大学法人東京大学 抗ウイルス剤又はウイルスcccDNA形成阻害剤
WO2020247444A1 (en) 2019-06-03 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
US11472808B2 (en) 2019-06-04 2022-10-18 Enanta Pharmaceuticals, Inc. Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents
US11760755B2 (en) 2019-06-04 2023-09-19 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2020255038A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
US20220305116A1 (en) * 2019-06-18 2022-09-29 Janssen Sciences lreland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators being sulfonamide derivatives
WO2020255039A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and quinazoline derivatives
US20210009718A1 (en) 2019-06-25 2021-01-14 Gilead Sciences, Inc. FLT3L-Fc FUSION PROTEINS AND METHODS OF USE
WO2021007488A1 (en) 2019-07-11 2021-01-14 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
US20220257619A1 (en) 2019-07-18 2022-08-18 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
EP4017476A1 (en) 2019-08-19 2022-06-29 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
EP4028394A4 (en) * 2019-09-04 2023-10-11 Taigen Biotechnology Co., Ltd. HEPATITIS B VIRUCIIDES
WO2021055425A2 (en) 2019-09-17 2021-03-25 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
US11497808B2 (en) 2019-09-30 2022-11-15 Gilead Sciences, Inc. HBV vaccines and methods treating HBV
EP4567109A3 (en) 2019-12-06 2025-09-17 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
MX2022007909A (es) 2019-12-24 2022-07-21 Hoffmann La Roche Combinacion farmaceutica de agentes antivirales que actuan sobre hbv y/o un inmunomodulador para el tratamiento de hbv.
WO2021160617A1 (en) * 2020-02-11 2021-08-19 Irbm S.P.A. Spirocyclic inhibitors of hepatitis b virus
WO2021188414A1 (en) 2020-03-16 2021-09-23 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
TW202421168A (zh) 2020-03-20 2024-06-01 美商基利科學股份有限公司 4’-c-經取代-2-鹵基-2’-去氧腺苷核苷之前藥及其製造與使用方法
WO2021197486A1 (zh) * 2020-04-03 2021-10-07 东莞市东阳光新药研发有限公司 新型螺环类化合物及其在药物中的应用
CN111393391B (zh) * 2020-04-16 2022-07-26 南京安纳康生物科技有限公司 用于乙型肝炎病毒感染的抗病毒剂
CN111349056B (zh) * 2020-04-16 2022-08-02 南京安纳康生物科技有限公司 用于乙型肝炎病毒感染的抗病毒剂
WO2021216661A1 (en) 2020-04-22 2021-10-28 Assembly Biosciences, Inc. Pyrazole carboxamide compounds for treatment of hbv
KR20230005881A (ko) 2020-04-22 2023-01-10 어셈블리 바이오사이언시스, 인크. Hbv의 치료를 위한 5원 헤테로아릴 카르복스아미드 화합물
CN115916341A (zh) 2020-04-22 2023-04-04 组装生物科学股份有限公司 用于治疗hbv的吡唑甲酰胺化合物
WO2021216660A1 (en) 2020-04-22 2021-10-28 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv
WO2022031894A1 (en) 2020-08-07 2022-02-10 Gilead Sciences, Inc. Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
EP4337223A1 (en) 2021-05-13 2024-03-20 Gilead Sciences, Inc. Combination of a tlr8 modulating compound and anti-hbv sirna therapeutics
EP4359411A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
MX2023014762A (es) 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
US11976072B2 (en) 2021-06-23 2024-05-07 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
EP4359413A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2023069547A1 (en) 2021-10-20 2023-04-27 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv
WO2023069545A1 (en) 2021-10-20 2023-04-27 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv
WO2023069544A1 (en) 2021-10-20 2023-04-27 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv
US20250163009A1 (en) 2022-02-25 2025-05-22 Assembly Biosciences, Inc. Benzothia(dia)zepine compounds for treatment of hbv and hdv
WO2023164179A1 (en) 2022-02-25 2023-08-31 Assembly Biosciences, Inc. Benzothia(dia)zepine compounds for treatment of hbv and hdv
WO2023164186A1 (en) 2022-02-25 2023-08-31 Assembly Biosciences, Inc. Benzothia(dia)zepine compounds for treatment of hbv and hdv
WO2023164181A1 (en) 2022-02-25 2023-08-31 Assembly Biosciences, Inc. Benzothia(dia)zepine compounds for treatment of hbv and hdv
CN115677545B (zh) * 2022-10-28 2024-03-15 潍坊医学院 一种抗hbv磺胺苯甲酰胺类衍生物及其制备方法和应用
WO2025043094A1 (en) 2023-08-23 2025-02-27 Assembly Biosciences, Inc. Benzothia(dia)zepine compounds for treatment of hbv and hdv
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
US20250345389A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies
WO2025240244A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin

Family Cites Families (223)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1359583A (en) * 1919-11-28 1920-11-23 James W Doolittle Force-feed oil-cup
US1359596A (en) * 1919-12-08 1920-11-23 Pressure Proof Piston Ring Com Piston-ring
US3843662A (en) 1971-12-09 1974-10-22 Pfizer 2-halo-5-(substituted piperidino sulfonyl)benzoic acids
AU1508183A (en) 1982-06-04 1983-12-08 Beecham Group Plc Benzamide and anilide derivatives of 8-azabicyclo-(3.2.1)- -octane
EP0135545A1 (en) 1983-02-19 1985-04-03 Beecham Group Plc Azabicycloalkyl benzamide and anilide derivatives
JPS62142164A (ja) 1985-12-13 1987-06-25 Ishihara Sangyo Kaisha Ltd 4,5−ジクロロイミダゾ−ル系化合物及びそれらを含有する有害生物防除剤
IN164880B (OSRAM) * 1986-01-30 1989-06-24 Ishihara Sangyo Kaisha
US5272167A (en) 1986-12-10 1993-12-21 Schering Corporation Pharmaceutically active compounds
CA1339133C (en) 1987-03-13 1997-07-29 Rikuo Nasu Imidazole compounds and biocidal composition comprising the same for controlling harmful organisms
JP2606720B2 (ja) * 1987-03-13 1997-05-07 石原産業株式会社 イミダゾール系化合物及びそれらを含有する有害生物防除剤
US5571821A (en) * 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
GB8904174D0 (en) 1989-02-23 1989-04-05 British Bio Technology Compounds
US4962101A (en) 1989-08-21 1990-10-09 Merck & Co., Inc. 2-(Heterocyclylalkyl)phenyl carbapenem antibacterial agents
GB9023082D0 (en) 1990-10-24 1990-12-05 Schering Agrochemicals Ltd Fungicides
GB9109557D0 (en) 1991-05-02 1991-06-26 Wellcome Found Chemical compounds
US5308826A (en) 1993-04-22 1994-05-03 Zeneca Limited Herbicidal 4-substituted pyridyl-3-carbinols
GB9405347D0 (en) * 1994-03-18 1994-05-04 Agrevo Uk Ltd Fungicides
WO1995032949A1 (en) 1994-05-27 1995-12-07 James Black Foundation Limited Gastrin and cck antagonists
US5795907A (en) 1994-05-27 1998-08-18 James Black Foundation Limited Gastin and CCK receptor ligands
KR0131723B1 (ko) * 1994-06-08 1998-04-14 김주용 반도체소자 및 그 제조방법
US5763618A (en) 1995-05-12 1998-06-09 Konica Corporation Manufacturing method of sulfides
US5723411A (en) 1995-10-31 1998-03-03 E. I. Du Pont De Nemours And Company Herbicidal pyridazinones
DE19540995A1 (de) 1995-11-03 1997-05-07 Hoechst Ag Substituierte Sulfonimidamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
GB9612884D0 (en) 1996-06-20 1996-08-21 Smithkline Beecham Plc Novel compounds
WO1997049695A1 (en) 1996-06-25 1997-12-31 Smithkline Beecham P.L.C. Sulfonamide derivatives as 5ht7 receptor antagonists
AU5127098A (en) 1996-11-29 1998-06-22 Smithkline Beecham Plc Use of a combination of penciclovir and alpha-interferon in the manufacture of a medicament for the treatment of hepatitis
US5939423A (en) 1997-04-16 1999-08-17 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis B infection with thymosin alpha 1 and famciclovir
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US5994396A (en) * 1997-08-18 1999-11-30 Centaur Pharmaceuticals, Inc. Furansulfonic acid derivatives and pharmaceutical compositions containing the same
AU759255B2 (en) 1998-01-29 2003-04-10 Amgen, Inc. PPAR-gamma modulators
BR9909666A (pt) 1998-03-26 2001-09-11 Japan Tobacco Inc Derivados de amida e antagonistas de nociceptina
US6251893B1 (en) 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
CZ300366B6 (cs) 1999-01-15 2009-05-06 Nycomed Gmbh Fenylfenanthridinová sloucenina, farmaceutický prostredek s jejím obsahem a její použití
KR20020015376A (ko) 1999-07-16 2002-02-27 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Mek 억제제를 사용한 만성 통증의 치료 방법
JP2003506406A (ja) 1999-08-10 2003-02-18 ザ・チャンセラー・マスターズ・アンド・スカラーズ・オブ・ザ・ユニバーシティ・オブ・オックスフォード 長鎖n−アルキル化合物およびそのオキサ誘導体
CA2385592C (en) 1999-09-17 2011-01-11 Bing-Yan Zhu Benzamides and related inhibitors of factor xa
PE20010628A1 (es) 1999-10-01 2001-06-18 Takeda Chemical Industries Ltd Compuestos de amina ciclica, su produccion y su uso
AU2018301A (en) 1999-12-28 2001-07-24 Pfizer Products Inc. Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
WO2001055121A1 (en) 2000-01-28 2001-08-02 Kaken Pharmaceutical Co., Ltd. Azepine derivatives
US6511980B2 (en) 2000-05-05 2003-01-28 Ortho Mcneil Pharmaceutical, Inc. Substituted diamine derivatives useful as motilin antagonists
EP1193268A1 (en) 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein Junkinases
WO2002051410A2 (en) 2000-12-22 2002-07-04 Akzo Nobel N.V. Phenylthiazole and thiazoline derivatives and their use as antiparasitics
DE60115501T2 (de) 2000-12-27 2006-07-13 Dainippon Sumitomo Pharma Co., Ltd. Neue Carbapenemverbindungen, Arzneimittel und antibakterielles Mittel, das diese enthält, und deren Verwendungen
AU2002248418A1 (en) * 2001-02-09 2002-08-28 Massachusetts Institute Of Technology Methods of identifying agents that mediate polypeptide aggregation
US6650463B2 (en) 2001-03-13 2003-11-18 Seiko Epson Corporation Electrophoretic display device
KR100713137B1 (ko) 2001-06-28 2007-05-02 동화약품공업주식회사 신규의 2,4-디플루오로벤즈아미드 유도체
WO2003007955A2 (en) 2001-07-20 2003-01-30 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
DE10136043A1 (de) 2001-07-25 2003-02-13 Degussa Verfahren zur Herstellung von modifiziertem Ruß
US6956035B2 (en) 2001-08-31 2005-10-18 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
EP1448560B1 (en) 2001-11-20 2005-06-15 Eli Lilly And Company 3-SUBSTITUTED OXINDOLE beta 3 AGONISTS
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
CN1658849A (zh) 2002-06-05 2005-08-24 株式会社医药分子设计研究所 Ap-1和nfat活化抑制剂
RU2340605C2 (ru) 2002-06-27 2008-12-10 Ново Нордиск А/С Арилкарбонильные производные в качестве терапевтических средств
EP1531815B1 (en) 2002-06-27 2014-09-24 Novo Nordisk A/S Glucokinase activators
WO2004010943A2 (en) 2002-07-31 2004-02-05 Smithkline Beecham Corporation Substituted benzanilides as modulators of the ccr5 receptor
WO2004011427A2 (en) 2002-07-31 2004-02-05 Smithkline Beecham Corporation Substituted benzanilides as modulators of the ccr5 receptor
US7186735B2 (en) 2002-08-07 2007-03-06 Sanofi-Aventis Deutschland Gmbh Acylated arylcycloalkylamines and their use as pharmaceuticals
US7338956B2 (en) 2002-08-07 2008-03-04 Sanofi-Aventis Deutschland Gmbh Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
JP4399862B2 (ja) 2002-08-09 2010-01-20 味の素株式会社 腸疾患および内臓痛の治療薬
US20040110802A1 (en) * 2002-08-23 2004-06-10 Atli Thorarensen Antibacterial benzoic acid derivatives
CN1694704A (zh) 2002-09-06 2005-11-09 詹森药业有限公司 (1h-苯并咪唑-2-基)-(哌嗪基)-甲酮衍生物及其相关化合物作为组胺h4受体拮抗剂用于治疗炎性和过敏性疾病
SE0202838D0 (sv) 2002-09-24 2002-09-24 Astrazeneca Ab Chemical compounds
US7378525B2 (en) 2002-12-23 2008-05-27 Millennium Pharmaceuticals, Inc. CCR8 inhibitors
US7320989B2 (en) 2003-02-28 2008-01-22 Encysive Pharmaceuticals, Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
US7595322B2 (en) 2003-03-27 2009-09-29 Cytokinetics, Inc. Heterocyclic sulfonamides as modulators of cardiac sarcomeres
WO2004099192A2 (en) 2003-04-30 2004-11-18 The Institutes Of Pharmaceutical Discovery, Llc Heterocycle substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
EP1620094A4 (en) 2003-05-06 2010-04-28 Glaxosmithkline Llc NEW CHEMICAL COMPOUNDS
US7368457B2 (en) 2003-05-13 2008-05-06 Schering Corporation Bridged N-arylsulfonylpiperidines as gamma-secretase inhibitors
WO2005007621A2 (en) 2003-05-30 2005-01-27 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
US20110275630A1 (en) 2003-06-02 2011-11-10 Abbott Laboratories Isoindolinone kinase inhibitors
EP1631559A4 (en) 2003-06-06 2008-08-27 Smithkline Beecham Corp IL-8 SB / SB RECEPTOR ANTAGONISTS
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
GB0319151D0 (en) 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
US8084457B2 (en) 2003-09-15 2011-12-27 Lead Discovery Center Gmbh Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
US7498050B2 (en) 2003-12-15 2009-03-03 Kraft Foods Global Brands Llc Edible spread composition and packaged product
DE102004009238A1 (de) 2004-02-26 2005-09-08 Merck Patent Gmbh Arylamid-Derivate
WO2005087217A1 (en) 2004-03-05 2005-09-22 The General Hospital Corporation Compositions and methods for modulating interaction between polypeptides
WO2005105785A2 (en) 2004-05-04 2005-11-10 Novo Nordisk A/S Indole derivatives for treatment of obesity
US20090105218A1 (en) 2004-05-29 2009-04-23 7Tm Pharma A/S CRTH2 Receptor Ligands For Therapeutic Use
WO2006002133A1 (en) 2004-06-22 2006-01-05 Schering Corporation Cannabinoid receptor ligands
SG155188A1 (en) 2004-07-30 2009-09-30 Exelixis Inc Pyrrole derivatives as pharmaceutical agents
AU2005278959A1 (en) 2004-08-31 2006-03-09 Astrazeneca Ab Quinazolinone derivatives and their use as B-Raf inhibitors
DE102004042441A1 (de) 2004-08-31 2006-04-06 Sanofi-Aventis Deutschland Gmbh Mit Aminosäuren substituierte Hexahydro-pyrazino(1,2-a)pyrimidin-4,7-dionderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
TW200626559A (en) 2004-10-13 2006-08-01 Wyeth Corp Anilino-pyrimidine analogs
WO2006049835A2 (en) 2004-10-19 2006-05-11 Novartis Vaccines And Diagnostics Inc. Indole and benzimidazole derivatives
TW200628463A (en) 2004-11-10 2006-08-16 Synta Pharmaceuticals Corp Heteroaryl compounds
US20060122236A1 (en) 2004-12-06 2006-06-08 Wood Michael R Substituted biaryl-carboxylate derivatives
AR053992A1 (es) 2004-12-22 2007-05-30 Astrazeneca Ab Compuestos quimicos con actividad anticancerosa, un procedimiento para su preparacion, su uso en la preparacion de medicamentos y composicion farmaceutica.
EP1831198B1 (en) 2004-12-22 2009-04-08 AstraZeneca AB Pyridine carboxamide derivatives for use as anticancer agents
FI117653B (fi) 2005-02-21 2006-12-29 Eigenor Oy Menetelmä ja laitteisto liikkuvien kohteiden havaitsemiseksi tutkalla
GB0510141D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
US20070032493A1 (en) 2005-05-26 2007-02-08 Synta Pharmaceuticals Corp. Method for treating B cell regulated autoimmune disorders
US7790726B2 (en) 2005-08-16 2010-09-07 Chemocentryx, Inc. Monocyclic and bicyclic compounds and methods of use
AU2006290442B2 (en) 2005-09-16 2010-07-29 Arrow Therapeutics Limited Biphenyl derivatives and their use in treating hepatitis C
AU2006326494A1 (en) 2005-12-12 2007-06-21 Genelabs Technologies, Inc. N-(6-membered aromatic ring)-amido anti-viral compounds
AU2006331770A1 (en) 2005-12-21 2007-07-05 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and H3 receptor antagonist/inverse agonist
US20090018118A1 (en) 2005-12-29 2009-01-15 Uros Urleb Heterocyclic compounds
EP2019830A4 (en) 2006-05-04 2011-01-19 Inst Hepatitis & Virus Res INHIBITORS OF THE SECRETION OF HEPATITIS B VIRUS ANTIGENS FOR THE TREATMENT OF A CHRONIC HEPATITIS VIRUS
US20080021063A1 (en) 2006-07-18 2008-01-24 Kazantsev Aleksey G Compositions and methods for modulating sirtuin activity
US8153803B2 (en) * 2006-07-18 2012-04-10 The General Hospital Corporation Compositions and methods for modulating sirtuin activity
FR2903985B1 (fr) 2006-07-24 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2904316B1 (fr) 2006-07-31 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique.
WO2008022171A1 (en) 2006-08-17 2008-02-21 Boehringer Ingelheim International Gmbh Methods of using aryl sulfonyl compounds effective as soluble epoxide hydrolase inhibitors
WO2008054605A2 (en) 2006-10-06 2008-05-08 Merck & Co., Inc. Non-nucleoside reverse transcriptase inhibitors
WO2008076270A2 (en) 2006-12-13 2008-06-26 Temple University-Of The Commonwealth System Of Higher Education Sulfide, sulfoxide and sulfone chalcone analogues, derivatives thereof and therapeutic uses thereof
US20100022517A1 (en) 2006-12-18 2010-01-28 Richards Lori A Ophthalmic formulation of rho kinase inhibitor compound
US8071779B2 (en) 2006-12-18 2011-12-06 Inspire Pharmaceuticals, Inc. Cytoskeletal active rho kinase inhibitor compounds, composition and use
FR2910473B1 (fr) 2006-12-26 2009-02-13 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique.
JP2008179621A (ja) 2006-12-28 2008-08-07 Taisho Pharmaceutical Co Ltd 含窒素飽和複素環化合物
US9001047B2 (en) 2007-01-07 2015-04-07 Apple Inc. Modal change based on orientation of a portable multifunction device
JP2008184403A (ja) 2007-01-29 2008-08-14 Japan Health Science Foundation 新規c型肝炎ウイルス阻害剤
AU2008225766B2 (en) 2007-03-15 2012-06-07 Novartis Ag Organic compounds and their uses
US8097728B2 (en) 2007-04-30 2012-01-17 Philadelphia Health & Education Corporation Iminosugar compounds with antiflavirus activity
JP5160637B2 (ja) 2007-05-04 2013-03-13 アイアールエム・リミテッド・ライアビリティ・カンパニー c−kitおよびPDGFRキナーゼインヒビターとしての化合物および組成物
WO2008154819A1 (fr) 2007-06-18 2008-12-24 Zhang, Zhongneng Thiazolyl-dihydropyrimidines à substitution carbéthoxy
WO2009018219A2 (en) * 2007-07-28 2009-02-05 University Of Chicago Methods and compositions for modulating rad51 and homologous recombination
EP2182935A1 (en) 2007-08-02 2010-05-12 F. Hoffmann-Roche AG The use of benzamide derivatives for the treatment of cns disorders
CN101429166B (zh) 2007-11-07 2013-08-21 上海特化医药科技有限公司 喹唑啉酮衍生物及其制备方法和用途
JP2011507910A (ja) 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター 真核生物の寿命を変更するための方法
FR2926555B1 (fr) 2008-01-22 2010-02-19 Sanofi Aventis Derives bicycliques de carboxamides azabicycliques, leur preparation et leur application en therapeutique
FR2926554B1 (fr) 2008-01-22 2010-03-12 Sanofi Aventis Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique
FR2926556B1 (fr) 2008-01-22 2010-02-19 Sanofi Aventis Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique
FR2926553B1 (fr) 2008-01-23 2010-02-19 Sanofi Aventis Derives d'indole-2-carboxamides et d'azaindole-2- carboxamides substitues par un groupe silanyle, leur preparation et leur application en therapeutique
CU20080028A6 (es) * 2008-02-29 2011-02-24 Ct Ingenieria Genetica Biotech Compuestos químicos obtenidos in silico para la preparación de composiciones farmacéuticas para atenuar o inhibir la infección por virus dengue y otros flavivirus
WO2009146013A1 (en) 2008-03-31 2009-12-03 Georgetown University Myosin light chain phosphatase inhibitors
CN102015638A (zh) 2008-04-24 2011-04-13 万有制药株式会社 以芳基磺酰基衍生物作为有效成分的长链脂肪酸延长酶抑制剂
US20090325960A1 (en) 2008-06-26 2009-12-31 Fulcher Emilee H Method for treating inflammatory diseases using rho kinase inhibitor compounds
US8299096B2 (en) 2008-06-26 2012-10-30 Inspire Pharmaceuticals, Inc. Method for treating pulmonary diseases using rho kinase inhibitor compounds
US8410147B2 (en) 2008-06-26 2013-04-02 Inspire Pharmaceuticals, Inc. Method for treating diseases associated with alterations in cellular integrity using Rho kinase inhibitor compounds
US20100008968A1 (en) 2008-06-26 2010-01-14 Lampe John W Method for treating cardiovascular diseases using rho kinase inhibitor compounds
US20090325959A1 (en) 2008-06-26 2009-12-31 Vittitow Jason L Method for treating ophthalmic diseases using rho kinase inhibitor compounds
US8207195B2 (en) 2008-06-26 2012-06-26 Inspire Pharmaceuticals, Inc. Method for treating neurological and neuropathic diseases using rho kinase inhibitor compounds
CA2735392A1 (en) 2008-08-15 2010-02-18 F. Hoffmann-La Roche Ag Bi-aryl aminotetralines
US9040488B2 (en) 2008-09-02 2015-05-26 Baruch S. Blumberg Institute Imino sugar derivatives demonstrate potent antiviral activity and reduced toxicity
US8143269B2 (en) * 2008-10-03 2012-03-27 Calcimedica, Inc. Inhibitors of store operated calcium release
WO2010043592A1 (en) 2008-10-15 2010-04-22 Revotar Biopharmaceuticals Ag Lipase inhibitors for use for the treatment of obesity
WO2010059658A1 (en) 2008-11-20 2010-05-27 Glaxosmithkline Llc Chemical compounds
EP2400969A4 (en) 2008-12-04 2012-05-16 Inspire Pharmaceuticals Inc METHOD FOR TREATING PULMONARY DISEASES USING RHO KINASE INHIBITORY COMPOUNDS
CA2748174A1 (en) 2008-12-30 2010-07-08 Arqule, Inc. Substituted 1h-pyrazolo[3,4-d]pyrimidine-6-amine compounds
WO2010088000A2 (en) 2009-02-02 2010-08-05 Angion Biomedica Corp. Antifibrotic compounds and uses thereof
WO2010123139A1 (ja) * 2009-04-24 2010-10-28 持田製薬株式会社 スルファモイル基を有するアリールカルボキサミド誘導体
WO2010133336A1 (en) 2009-05-19 2010-11-25 Bayer Cropscience Ag Insecticidal arylpyrrolines
CN102480957A (zh) 2009-05-27 2012-05-30 Ptc医疗公司 治疗癌症及非肿瘤病症的方法
CN102469788A (zh) 2009-06-30 2012-05-23 西佳技术公司 登革病毒感染的治疗和预防
US8703938B2 (en) 2009-09-11 2014-04-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8822700B2 (en) 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011035143A2 (en) 2009-09-17 2011-03-24 The Regents Of The University Of Michigan Methods and compositions for inhibiting rho-mediated diseases and conditions
WO2011058766A1 (en) 2009-11-16 2011-05-19 Raqualia Pharma Inc. Aryl carboxamide derivatives as ttx-s blockers
CN102093320B (zh) 2009-12-09 2013-08-28 扬子江药业集团上海海尼药业有限公司 一种可溶性环氧化物水解酶抑制剂
WO2011088015A1 (en) 2010-01-15 2011-07-21 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
WO2011088561A1 (en) 2010-01-20 2011-07-28 University Of Manitoba Anti-viral compounds and compositions
WO2011109237A2 (en) 2010-03-02 2011-09-09 Emory University Uses of noscapine and derivatives in subjects diagnosed with fap
JP2013522192A (ja) 2010-03-11 2013-06-13 ブリストル−マイヤーズ スクイブ カンパニー C型肝炎の処置のための化合物
CN102206172B (zh) * 2010-03-30 2015-02-25 中国医学科学院医药生物技术研究所 一组取代双芳基化合物及其制备方法和抗病毒应用
JP2013523766A (ja) 2010-03-31 2013-06-17 グラクソ グループ リミテッド キナーゼ阻害剤としてのイミダゾリル‐イミダゾール
PH12012502194A1 (en) 2010-05-07 2014-09-05 Glaxosmithkline Llc Indoles
WO2011155898A1 (en) 2010-06-11 2011-12-15 Wadell Goeran New antiviral compounds
US20130142827A1 (en) 2010-06-25 2013-06-06 Philadelphia Health & Education Corporation D/B/A Induction of immune response
WO2012012282A1 (en) 2010-07-19 2012-01-26 Inspire Pharmaceuticals, Inc. Bifunctional rho kinase inhibitor compounds, composition and use
JP2013536178A (ja) 2010-07-26 2013-09-19 ニューロセラピューティクス ファーマ, インコーポレイテッド アリールスルホンアミド誘導体、組成物、および使用方法
BR112013001015A2 (pt) 2010-07-27 2016-05-24 Inspire Pharmaceuticals Inc método por tratar doenças oftálmicas que usam compostos de inibidor de cinase em formas de prodrug
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
WO2012033956A1 (en) 2010-09-08 2012-03-15 Mithridion, Inc. Cognition enhancing compounds and compositions, methods of making, and methods of treating
WO2012047856A2 (en) 2010-10-04 2012-04-12 Institute For Hepatitis And Virus Research Novel inhibitors of secretion of hepatitis b virus antigens
GB201017345D0 (en) 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
EP2646439B1 (en) 2010-12-02 2016-05-25 Bristol-Myers Squibb Company Alkyl amides as hiv attachment inhibitors
WO2012080050A1 (en) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Solid forms of a phenoxybenzenesulfonyl compound
GB201103419D0 (OSRAM) 2011-02-28 2011-04-13 Univ Aberdeen
PH12013502033A1 (en) 2011-04-08 2014-01-06 Janssen Sciences Ireland Uc Pyrimidine derivatives for the treatment of viral infections
US8889716B2 (en) 2011-05-10 2014-11-18 Chdi Foundation, Inc. Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof
EP2726459B1 (en) 2011-07-01 2019-09-11 Baruch S. Blumberg Institute Sulfamoylbenzamide derivatives as antiviral agents against hbv infection
CN106957282B (zh) * 2011-12-21 2019-08-30 诺维拉治疗公司 B型肝炎抗病毒剂
ES2581489T3 (es) 2012-01-06 2016-09-06 Janssen Sciences Ireland Uc 1,4-dihidropirimidinas 4,4-disustituidas y el uso de las mismas como medicamentos para el tratamiento de la hepatitis B
JP6134338B2 (ja) * 2012-02-29 2017-05-24 バルーク エス.ブルームバーグ インスティテュート B型肝炎ウイルス共有結合閉環状dna形成の阻害剤およびそれらの使用方法
US20130267517A1 (en) 2012-03-31 2013-10-10 Hoffmann-La Roche Inc. Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
CA2865259A1 (en) 2012-03-31 2013-10-03 F. Hoffmann-La Roche Ag Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
PL2861611T3 (pl) 2012-05-25 2017-08-31 Janssen Sciences Ireland Uc Nukleozydy uracylowe spirooksetanu
WO2013181584A2 (en) 2012-06-01 2013-12-05 Guo, Ju-Tao Modulation of hepatitis b virus cccdna transcription
JO3300B1 (ar) 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
TW201408652A (zh) 2012-07-11 2014-03-01 Hoffmann La Roche 作爲RORc調節劑之芳基磺內醯胺衍生物
AR092270A1 (es) * 2012-08-28 2015-04-08 Janssen R&D Ireland Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
UA115069C2 (uk) 2012-08-28 2017-09-11 ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі Конденсовані біциклічні похідні сульфамоїлу та їх застосування як лікарських препаратів для лікування гепатиту b
EP2892893B2 (en) 2012-09-10 2019-10-16 F.Hoffmann-La Roche Ag 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
SG11201504740UA (en) * 2012-12-27 2015-07-30 Univ Drexel Novel antiviral agents against hbv infection
ES2628953T3 (es) * 2013-02-28 2017-08-04 Janssen Sciences Ireland Uc Sulfamoilarilamidas y el uso de las mismas como medicamentos para el tratamiento de la hepatitis B
BR112015020545A2 (pt) 2013-02-28 2017-07-18 Eisai R&D Man Co Ltd derivado de tetraidroimidazo[1,5-d][1,4]oxazepina
WO2014165128A2 (en) 2013-03-12 2014-10-09 Novira Therapeutics, Inc. Hepatitis b antiviral agents
US9944658B2 (en) 2013-03-14 2018-04-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
MX353412B (es) 2013-04-03 2018-01-10 Janssen Sciences Ireland Uc Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
MX2015015692A (es) 2013-05-17 2016-03-04 Hoffmann La Roche Novedosas heteroarildihidropirimidinas, unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de hepatitis b.
JO3603B1 (ar) * 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
JP6441315B2 (ja) 2013-05-17 2018-12-19 ヤンセン・サイエンシズ・アイルランド・ユーシー スルファモイルチオフェンアミド誘導体およびb型肝炎を治療するための医薬品としてのその使用
US9688681B2 (en) 2013-05-28 2017-06-27 Bayer Cropscience Aktiengesellschaft Heterocyclic compounds as pest control agents
LT3004090T (lt) 2013-05-28 2018-01-10 Astrazeneca Ab Cheminiai junginiai
WO2014198880A1 (en) 2013-06-14 2014-12-18 Ferrer Internacional, S.A. 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity
PL3024819T3 (pl) 2013-07-25 2018-08-31 Janssen Sciences Ireland Uc Pochodne piroloamidowe podstawione glioksamidem i ich zastosowanie jako leków do leczenia wirusowego zapalenia wątroby typu B
WO2015057945A1 (en) 2013-10-18 2015-04-23 Indiana University Research And Technology Corporation Hepatitis b viral assembly effectors
WO2015055764A1 (en) 2013-10-18 2015-04-23 Syngenta Participations Ag 3-methanimidamid-pyridine derivatives as fungicides
SG11201602748XA (en) 2013-10-23 2016-05-30 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
US9115113B2 (en) 2013-11-14 2015-08-25 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
JO3466B1 (ar) 2013-12-20 2020-07-05 Takeda Pharmaceuticals Co مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
DK3099296T3 (en) 2014-01-31 2019-04-15 Cognition Therapeutics Inc ISO-INDOLINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE
KR20160128305A (ko) 2014-02-05 2016-11-07 노비라 테라퓨틱스, 인코포레이티드 Hbv 감염의 치료를 위한 병용 요법
ES2705401T3 (es) 2014-02-06 2019-03-25 Janssen Sciences Ireland Uc Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la Hepatitis B
HUE041734T2 (hu) 2014-03-07 2019-05-28 Hoffmann La Roche Új, 6-tagú gyûrûvel kondenzált heteroarildihidropirimidinek hepatitisz B vírusfertõzés kezelésére és megelõzésére
PT3116316T (pt) 2014-03-13 2019-09-30 Assembly Biosciences Inc Moduladores alostéricos da proteína do núcleo da hepatite b
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
KR20160133563A (ko) 2014-03-28 2016-11-22 선샤인 레이크 파르마 컴퍼니 리미티드 다이하이드로피리미딘 화합물 및 이의 약제학적 용도
CA2950807C (en) 2014-05-30 2022-05-31 Medshine Discovery Inc. Dihydropyrimido fused ring derivative as hbv inhibitor
WO2016089990A1 (en) 2014-12-02 2016-06-09 Novira Therapeutics, Inc. Sulfide alkyl and pyridyl reverse sulfonamide compounds for hbv treatment
US9550779B2 (en) 2014-12-30 2017-01-24 Novira Therapeutics, Inc. Derivatives and methods of treating hepatitis B infections
MA41338B1 (fr) 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
EP3271019A1 (en) 2015-03-19 2018-01-24 Novira Therapeutics Inc. Azocane and azonane derivatives and methods of treating hepatitis b infections
WO2016161268A1 (en) 2015-04-01 2016-10-06 Enanta Pharmaceuticals, Inc. Hepatitis b antviral agents
US10273228B2 (en) 2015-04-17 2019-04-30 Indiana University Research And Technology Corporation Hepatitis B viral assembly effectors
US10738035B2 (en) 2015-05-13 2020-08-11 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
JP6845231B2 (ja) 2015-09-29 2021-03-17 ノヴィラ・セラピューティクス・インコーポレイテッド B型肝炎抗ウイルス薬の結晶形態
CN109251212A (zh) 2017-07-14 2019-01-22 上海长森药业有限公司 内环硫醚酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途

Similar Documents

Publication Publication Date Title
JP2015531773A5 (OSRAM)
JP2016518437A5 (OSRAM)
EA027280B1 (ru) Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
IL264541A (en) History of sulfamolepyrolamide and their use as drugs for the treatment of jaundice b
JP2016518434A5 (OSRAM)
RU2019100164A (ru) Гетероциклическое соединение, используемое как ингибитор fgfr
JP2016506369A5 (OSRAM)
JP2019524883A5 (OSRAM)
EA201290260A1 (ru) Бензимидазол-имидазольные производные
EP4458348A3 (en) Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof
JP2016518385A5 (OSRAM)
JP2015520140A5 (OSRAM)
PE20181093A1 (es) Compuestos heterociclicos y usos de los mismos
JP2015143283A5 (OSRAM)
JP2015537020A5 (OSRAM)
WO2016105528A3 (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
MY187617A (en) Bridged ring compounds as hepatitis c virus (hcv) inhibitors and pharmaceutical applications thereof
JP2019522055A5 (OSRAM)
JP2016540742A5 (OSRAM)
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
AR081426A1 (es) Derivados de pirazol inhibidores del receptor sigma
JP2015509535A5 (OSRAM)
JP2016516043A5 (OSRAM)
NZ627750A (en) Carbamate compounds and of making and using same
JP2016501185A5 (OSRAM)